Abstract
An Integrated Analysis of Darbepoetin Alfa (DAR) in the Treatment of Anemia in Patients with Low- or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have